Singapore approves Bavarian's mpox vaccine Jynneos
Vials of the JYNNEOS smallpox and monkeypox vaccine are placed on a table during a clinic offered by the Pima County Department of Public Health at Abrams Public Health Center in Tucson,... Purchase Licensing Rights Read more
COPENHAGEN, Aug 27 (Reuters) - Danish biotech Bavarian Nordic (BAVA.CO) said on Tuesday its mpox vaccine Jynneos had been approved by Singapore's medicines regulatory authority for use in the country.
The vaccine was approved to prevent smallpox and mpox in individuals at the age of 18 or older who are determined to be at high risk for the disease, marking the transition to a full approval for Jynneos in Singapore, Bavarian said in a statement.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik
Our Standards: The Thomson Reuters Trust Principles.
No comments:
Post a Comment